U.S. Capitol Building DrugmakersAbbVie, AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson,Merck, Pfizer and Sanofi appeared before the Senate FinanceCommittee as lawmakers mull how to best control rising drug prices.(Photo: Mike Scarcella/ALM)

Senators got their first opportunity Tuesday to prod drugmakers about the wallet-emptyingprices they charge for prescription drugs.

Almost in unison, the executives expressed support for eliminating rebates that flow to industrymiddlemen instead of patients; for increasing transparency abouthow they set prices; for shifting to a more value-based pricingsystem, in which outcomes are rewarded. Together they demurred whenasked to commit to lowering list prices on drugs like insulin andthe blockbuster rheumatoid arthritis drug Humira.

Continue Reading for Free

Register and gain access to:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Core and Group Health
Health Care Reform
Cost-Containment
Investment Instruments